中和抗体市場レポート：2031年までの動向、予測、競合分析

世界の中和抗体市場の将来は、病院・診療所、研究機関、診断研究所、製薬会社の各市場における機会で有望視されています。世界の中和抗体市場は、2025年から2031年にかけてCAGR 11.2%で成長すると予想されます。この市場の主な促進要因は、関節リウマチ、多発性硬化症、ループスなどの自己免疫疾患の罹患率の増加、感染症の有病率の上昇、従来のワクチンや薬剤と比較した抗体ベースの治療の利点に対する認識の高まりです。

• Lucintel社では、用途別では治療分野が予測期間中も最大規模を維持すると予測しています。
• 最終用途カテゴリーでは、製薬会社が引き続き最大セグメントとなります。
• 地域別では、大手企業の存在と国全体の強固なヘルスケアシステムにより、北米が予測期間中最大の地域であり続けると思われます。

中和抗体市場の戦略的成長機会

中和抗体市場の戦略的成長は、さまざまな治療分野への応用によって推進されています。企業は、感染症、腫瘍、個別化医療に主要な成長機会を見出し、市場でのプレゼンスを拡大しています。

• 感染症治療：感染症、特にCOVID-19の増加により、中和抗体には大きな成長機会が生まれています。企業は世界の需要に対応するため、迅速な承認取得と抗体の大量生産に注力しています。
• がん領域：中和抗体の主要な成長分野であるがん領域は、治療が困難ながん患者に有望な治療法を提供する標的治療薬であり続けています。がん細胞を選択的に攻撃できる抗体の開発は、主要な促進要因です。
• 自己免疫疾患：中和抗体は自己免疫疾患の治療にますます使用されるようになっており、副作用を最小限に抑え、患者の予後を改善する標的療法を提供します。
• 慢性疾患：糖尿病や心血管疾患などの慢性疾患における中和抗体の使用は増加しており、長期的な健康転帰を改善する新たな治療選択肢を提供しています。
• 個別化医療：個別化医療の進歩により、個々の患者の遺伝子プロファイルに合わせた中和抗体の成長機会が生まれ、様々な疾患における治療の精度と有効性が向上しています。

このような戦略的成長機会は、技術革新を促進し、多様な治療領域で中和抗体の使用を拡大し、市場の継続的拡大に向けて位置づけられています。

中和抗体市場の促進要因・課題

中和抗体市場は、技術の進歩、規制状況、経済状況など、さまざまな要因の影響を受けます。これらの市場促進要因・課題は、市場の今後の成長軌道を形成する上で極めて重要な役割を果たします。

中和抗体市場を牽引している要因は以下の通りです：

• COVID-19治療薬に対する需要の高まり：世界のパンデミックにより、中和抗体、特にCOVID-19治療に対する需要が煽られ、研究の増加や迅速な規制当局の承認につながっています。
• バイオテクノロジーの進歩：バイオテクノロジーの絶え間ない進歩により、より効果的で標的を絞った中和抗体の開発が可能になり、市場の成長を牽引しています。
• がん治療：がん治療における中和抗体の使用拡大は主要な促進要因であり、有望な臨床結果が新たな承認と市場拡大につながります。
• 政府の支援と資金援助：各国政府は、特に感染症やがん領域での抗体研究への資金拠出を増やしており、研究開発努力を後押しして市場成長を加速させています。
• 共同パートナーシップ：製薬企業と研究機関の共同研究により、新規抗体療法の迅速な開発と商業化が可能になりつつあります。

中和抗体市場の課題は以下の通りです：

• 高い開発コスト：開発コストの高さ：中和抗体の開発には研究開発や臨床試験に多額の投資が必要であり、中小企業にとっては課題となっています。
• 規制上のハードル：生物学的製剤の複雑な規制状況に対応することは、製品承認を遅らせる可能性があり、新規治療薬の市場投入までの時間に影響を与えます。
• 製造の複雑さ：中和抗体の製造には複雑な工程が伴うため、特に新興市場では製造規模の拡大が課題となります。

中和抗体市場は、技術の進歩、政府の支援、新規治療に対する需要の高まりによって牽引されています。しかし、市場が潜在力を十分に発揮するためには、高い開発コストや規制上のハードルといった課題に対処する必要があります。

目次

第1章 エグゼクティブサマリー

第2章 世界の中和抗体市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2019年から2031年までの市場動向と予測分析

• マクロ経済動向（2019-2024年）と予測（2025-2031年）
• 世界の中和抗体市場の動向（2019-2024年）と予測（2025-2031年）
• 世界の中和抗体市場、標的ウイルス別
  • SARS-CoV-2
  • HIV
  • インフルエンザ
  • エボラ
  • ジカ熱
  • C型肝炎
• 世界の中和抗体市場、抗体タイプ別
  • モノクローナル抗体
  • ポリクローナル抗体
• 世界の中和抗体市場、用途別
  • 治療
  • 診断
  • 研究開発
  • その他
• 世界の中和抗体市場、最終用途別
  • 病院と診療所
  • 調査機関
  • 診断検査室
  • 製薬会社
  • その他

第4章 2019年から2031年までの市場動向と予測分析、地域別

• 世界の中和抗体市場、地域別
• 北米の中和抗体市場
• 欧州の中和抗体市場
• アジア太平洋地域の中和抗体市場
• その他地域の中和抗体市場

第5章 競合分析

• 製品ポートフォリオ分析
• 業務統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
  • 世界の中和抗体市場の成長機会、標的ウイルス別
  • 世界の中和抗体市場の成長機会、抗体タイプ別
  • 世界の中和抗体市場の成長機会、用途別
  • 世界の中和抗体市場の成長機会、最終用途別
  • 世界の中和抗体市場の成長機会、地域別
• 世界の中和抗体市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界の中和抗体市場の生産能力拡大
  • 世界の中和抗体市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• Regeneron Pharmaceuticals
• Eli Lilly and Company
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Roche
• Novartis
• Merck
• Pfizer
• Johnson & Johnson

The future of the global neutralizing antibody market looks promising with opportunities in the hospital and clinic, research institute, diagnostic laboratory, and pharmaceutical company markets. The global neutralizing antibody market is expected to grow with a CAGR of 11.2% from 2025 to 2031. The major drivers for this market are the growing incidence of autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, and lupus, the rising prevalence of infectious diseases, and the increasing awareness of the benefits of antibody-based therapies compared to traditional vaccines and drugs.

• Lucintel forecasts that, within the application category, the therapeutic segment will remain the largest segment over the forecast period.
• Within the end-use category, pharmaceutical companies will remain the largest segment.
• In terms of regions, North America will remain the largest region over the forecast period due to the presence of major firms and a robust healthcare system across the country.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Neutralizing Antibody Market

The neutralizing antibody market is transforming due to technological innovations and a shift in healthcare priorities. These emerging trends are reshaping how companies develop and commercialize neutralizing antibody therapies globally.

• Increased Focus on COVID-19 Antibodies: With the global pandemic, there has been a surge in research for neutralizing antibodies targeting COVID-19. Companies are fast-tracking clinical trials and securing emergency use authorizations, making this a dominant trend in the market.
• Expansion in Oncology Treatments: Neutralizing antibodies are being increasingly utilized in oncology treatments. Companies are developing targeted therapies that attack specific cancer cells, offering more effective and less toxic treatment options.
• Personalized Medicine: The move toward personalized medicine is driving the development of antibodies tailored to individual patients' needs, particularly in cancer and autoimmune disorders. This trend enhances treatment efficacy and reduces side effects.
• Collaborations and Partnerships: The industry is seeing a rise in collaborations between biotech firms, pharmaceutical companies, and research institutions. These partnerships are speeding up innovation and enabling broader market access for new therapies.
• Technological Advancements in Biologics: Advancements in biologics manufacturing, including the use of cell-based and gene-editing technologies, are improving the efficiency and scalability of neutralizing antibody production, lowering costs, and boosting supply.

These trends are reshaping the neutralizing antibody market, with a focus on innovation, personalized treatments, and strategic collaborations, leading to more effective therapies and broader market penetration.

Recent Developments in the Neutralizing Antibody Market

The neutralizing antibody market has seen major advancements across various therapeutic areas, with key developments driving growth. Companies are focusing on innovation, partnerships, and regulatory milestones to capitalize on emerging opportunities in this fast-evolving market.

• COVID-19 Antibody Approvals: Several neutralizing antibodies have received emergency use authorizations for COVID-19 treatment, with major pharmaceutical companies launching new products that show efficacy in reducing viral loads.
• Oncology Innovations: Breakthroughs in neutralizing antibodies for oncology have been achieved, with new therapies targeting specific cancer cells, showing high effectiveness in clinical trials and receiving regulatory approvals in major markets.
• Collaborative Research Initiatives: There has been an increase in collaborative initiatives between biotech companies and academic institutions, particularly in the U.S. and Europe, aimed at accelerating antibody research for infectious diseases and cancers.
• Technological Advances in Manufacturing: Advances in biologics manufacturing have reduced production costs and improved scalability, making neutralizing antibodies more accessible and affordable for a wider range of treatments.
• Government Support for Biotechnology: Governments worldwide are increasing funding and support for biotechnology research, driving growth in the neutralizing antibody market as companies receive grants and tax incentives for R&D.

These developments are significantly impacting the neutralizing antibody market, fostering innovation, improving treatment outcomes, and enabling companies to capture new market opportunities globally.

Strategic Growth Opportunities for Neutralizing Antibody Market

Strategic growth in the neutralizing antibody market is being driven by its applications across various therapeutic areas. Companies are identifying key growth opportunities in infectious diseases, oncology, and personalized medicine, allowing them to expand their market presence.

• Infectious Disease Treatments: The rise of infectious diseases, particularly COVID-19, has created immense growth opportunities for neutralizing antibodies. Companies are focusing on fast-tracked approvals and large-scale production of antibodies to meet global demand.
• Oncology: Oncology remains a major growth area for neutralizing antibodies, with targeted therapies offering promising outcomes for patients with difficult-to-treat cancers. The development of antibodies that can selectively attack cancer cells is a key growth driver.
• Autoimmune Diseases: Neutralizing antibodies are increasingly being used in the treatment of autoimmune diseases, providing targeted therapies that minimize side effects and improve patient outcomes.
• Chronic Diseases: The use of neutralizing antibodies in chronic diseases, such as diabetes and cardiovascular conditions, is growing, offering new treatment options that improve long-term health outcomes.
• Personalized Medicine: Advances in personalized medicine are creating growth opportunities for neutralizing antibodies tailored to individual patients' genetic profiles, enhancing the precision and efficacy of treatments across various diseases.

These strategic growth opportunities are driving innovation and expanding the use of neutralizing antibodies across diverse therapeutic areas, positioning the market for continued expansion.

Neutralizing Antibody Market Driver and Challenges

The neutralizing antibody market is influenced by a variety of factors, including technological advancements, regulatory landscapes, and economic conditions. These drivers and challenges play a crucial role in shaping the market's future growth trajectory.

The factors responsible for driving the neutralizing antibody market include:

• Rising Demand for COVID-19 Therapies: The global pandemic has fueled demand for neutralizing antibodies, particularly for COVID-19 treatments, leading to increased research and rapid regulatory approvals.
• Advancements in Biotechnology: Continuous advancements in biotechnology are enabling the development of more effective and targeted neutralizing antibodies, driving market growth.
• Oncology Therapies: The expanding use of neutralizing antibodies in oncology is a major driver, with promising clinical results leading to new approvals and market expansion.
• Government Support and Funding: Governments are increasing funding for antibody research, particularly in infectious diseases and oncology, boosting R&D efforts and accelerating market growth.
• Collaborative Partnerships: Collaborations between pharmaceutical companies and research institutions are enabling faster development and commercialization of new antibody therapies.

Challenges in the neutralizing antibody market are:

• High Development Costs: The development of neutralizing antibodies requires significant investment in R&D and clinical trials, posing a challenge for smaller companies.
• Regulatory Hurdles: Navigating the complex regulatory landscape for biologics can slow down product approvals, impacting time-to-market for new therapies.
• Manufacturing Complexity: The production of neutralizing antibodies involves complex processes, making scaling up manufacturing a challenge, particularly in emerging markets.

The neutralizing antibody market is driven by technological advancements, government support, and rising demand for novel therapies. However, challenges such as high development costs and regulatory hurdles must be addressed for the market to reach its full potential.

List of Neutralizing Antibody Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies neutralizing antibody companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neutralizing antibody companies profiled in this report include-

• Regeneron Pharmaceuticals
• Eli Lilly and Company
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Roche
• Novartis
• Merck
• Pfizer
• Johnson & Johnson

Neutralizing Antibody by Segment

The study includes a forecast for the global neutralizing antibody market by target virus, antibody type, application, end use, and region.

Neutralizing Antibody Market by Target Virus [Analysis by Value from 2019 to 2031]:

• SARS-CoV-2
• HIV
• Influenza
• Ebola
• Zika
• Hepatitis C

Neutralizing Antibody Market by Antibody Type [Analysis by Value from 2019 to 2031]:

• Monoclonal Antibodies
• Polyclonal Antibodies

Neutralizing Antibody Market by Application [Analysis by Value from 2019 to 2031]:

• Therapeutics
• Diagnostics
• Research and Development
• Others

Neutralizing Antibody Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals and Clinics
• Research Institutes
• Diagnostic Laboratories
• Pharmaceutical Companies
• Others

Neutralizing Antibody Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Neutralizing Antibody Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are highlights of recent developments by major neutralizing antibody producers in key regions: the USA, China, India, Japan, and Germany.

• United States: In the U.S., recent advancements in neutralizing antibody research are driven by increased investment in COVID-19 therapies. The FDA has fast-tracked approvals for several monoclonal antibodies, further boosting the market as companies focus on cancer therapies and infectious disease treatments.
• China: In China, the neutralizing antibody market is witnessing rapid growth as local biotech companies invest in R&D and clinical trials for COVID-19 antibodies. Government support for innovation in biologics is accelerating the commercialization of neutralizing antibodies across multiple therapeutic areas.
• Germany: Germany's neutralizing antibody market is driven by collaborations between academic institutions and biotech companies. The country has made significant strides in developing antibodies for oncology and infectious diseases, with a focus on personalized medicine and targeted therapies.
• India: India's neutralizing antibody market is growing due to increased efforts in biotechnology and biopharma. The country is seeing a rise in clinical trials for COVID-19 therapies and a growing focus on antibody-based treatments for autoimmune and chronic diseases.
• Japan: Japan's neutralizing antibody market is experiencing growth driven by government initiatives to advance biotechnology and biopharmaceutical research. Major pharmaceutical companies are focusing on innovative monoclonal antibody treatments for cancer and other chronic conditions, contributing to market expansion.

Features of the Global Neutralizing Antibody Market

Market Size Estimates: Neutralizing antibody market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Neutralizing antibody market size by target virus, antibody type, application, end use, and region in terms of value ($B).

Regional Analysis: Neutralizing antibody market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different target virus, antibody type, application, end use, and regions for the neutralizing antibody market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neutralizing antibody market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the neutralizing antibody market by target virus (SARS-CoV-2, HIV, influenza, Ebola, zika, and hepatitis C), antibody type (monoclonal antibodies and polyclonal antibodies), application (therapeutics, diagnostics, research and development, and others), end use (hospitals and clinics, research institutes, diagnostic laboratories, pharmaceutical companies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Neutralizing Antibody Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Neutralizing Antibody Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Neutralizing Antibody Market by Target Virus
  • 3.3.1: SARS-CoV-2
  • 3.3.2: HIV
  • 3.3.3: Influenza
  • 3.3.4: Ebola
  • 3.3.5: Zika
  • 3.3.6: Hepatitis C
• 3.4: Global Neutralizing Antibody Market by Antibody Type
  • 3.4.1: Monoclonal Antibodies
  • 3.4.2: Polyclonal Antibodies
• 3.5: Global Neutralizing Antibody Market by Application
  • 3.5.1: Therapeutics
  • 3.5.2: Diagnostics
  • 3.5.3: Research and Development
  • 3.5.4: Others
• 3.6: Global Neutralizing Antibody Market by End Use
  • 3.6.1: Hospitals and Clinics
  • 3.6.2: Research Institutes
  • 3.6.3: Diagnostic Laboratories
  • 3.6.4: Pharmaceutical Companies
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Neutralizing Antibody Market by Region
• 4.2: North American Neutralizing Antibody Market
  • 4.2.1: North American Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.2.2: North American Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
• 4.3: European Neutralizing Antibody Market
  • 4.3.1: European Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.3.2: European Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
• 4.4: APAC Neutralizing Antibody Market
  • 4.4.1: APAC Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.4.2: APAC Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
• 4.5: ROW Neutralizing Antibody Market
  • 4.5.1: ROW Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.5.2: ROW Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Neutralizing Antibody Market by Target Virus
  • 6.1.2: Growth Opportunities for the Global Neutralizing Antibody Market by Antibody Type
  • 6.1.3: Growth Opportunities for the Global Neutralizing Antibody Market by Application
  • 6.1.4: Growth Opportunities for the Global Neutralizing Antibody Market by End Use
  • 6.1.5: Growth Opportunities for the Global Neutralizing Antibody Market by Region
• 6.2: Emerging Trends in the Global Neutralizing Antibody Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Neutralizing Antibody Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neutralizing Antibody Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Regeneron Pharmaceuticals
• 7.2: Eli Lilly and Company
• 7.3: AstraZeneca
• 7.4: GlaxoSmithKline
• 7.5: Sanofi
• 7.6: Roche
• 7.7: Novartis
• 7.8: Merck
• 7.9: Pfizer
• 7.10: Johnson & Johnson